Plate Nº 41 · recorded October 10, 2026
Health & Medicine ResearchReported finding
Lancet Publishes Results of Semaglutide Trials in Early Alzheimer's
The Lancet has published EVOKE and EVOKE+ results: two Phase 3 trials of oral semaglutide 14 mg in early-stage symptomatic Alzheimer's disease.
By Elena Vasquez3 min read566 words
In brief
- The Lancet published results of the EVOKE and EVOKE+ Phase 3 trials of oral semaglutide in early-stage symptomatic Alzheimer's disease.
- The trials tested a 14 mg oral dose of semaglutide, given flexibly.
- Both trials were randomised, placebo-controlled studies.
- Semaglutide is a GLP-1 receptor agonist already approved for diabetes and weight management.
The Lancet has published the results of two Phase 3 trials — dubbed EVOKE and EVOKE+ — that tested a 14 mg daily oral dose of semaglutide in people with early-stage symptomatic Alzheimer's disease. The trials were randomised and placebo-controlled, meaning participants were assigned by chance to receive either the drug or an inactive dummy pill, and neither they nor their doctors knew which one they got.
Semaglutide belongs to a class of medicines called GLP-1 receptor agonists. In plain terms, these drugs mimic a gut hormone that helps regulate blood sugar and appetite. Doctors already prescribe semaglutide for type 2 diabetes and, at higher doses, for weight management. The version used in these trials is the oral formulation, taken as a once-daily tablet rather than as a weekly injection.
The published paper reports on both the efficacy — whether the drug actually slowed or changed the course of the disease — and the safety of the 14 mg flexible dose in patients whose Alzheimer's was at an early symptomatic stage. That stage covers people who already show noticeable memory and thinking problems, spanning mild cognitive impairment due to Alzheimer's through mild dementia.
Why test a diabetes drug for Alzheimer's?
Researchers have eyed GLP-1 drugs for brain diseases for years. The reasoning: these medications appear to act on pathways involved in inflammation, blood vessel health and cellular energy metabolism — processes that also play a role in neurodegenerative disease.
The EVOKE programme applied that hypothesis to Alzheimer's directly. Each trial enrolled patients with early-stage symptomatic disease, randomised them to oral semaglutide or placebo, and tracked them over time on standard measures of cognition and daily function.
The Lancet paper presents the combined verdict of EVOKE and EVOKE+ on two questions researchers always ask in this order:
- Did it work? Cognitive and functional outcome measures compared between the semaglutide and placebo groups.
- Was it tolerated? Adverse events recorded across both arms of both trials.
What should readers keep in mind?
Any single pair of trials, however large and well-designed, has limits. Results from Phase 3 studies apply to the specific population tested — here, people with early symptomatic Alzheimer's — and do not automatically extend to later disease stages or to other patient groups.
Readers should also note the distinction between the drug's approved uses and its experimental ones. Regulators have approved semaglutide for diabetes and obesity; the EVOKE trials investigated a separate, unapproved indication, and regulatory decisions would follow their own review of the full data.
For the complete findings — including the efficacy outcomes, safety profile and the investigators' own interpretation of the limitations — readers should consult the full paper in The Lancet.
The bigger picture
Alzheimer's research has entered a period of mixed results. Some experimental therapies have shown modest effects on disease biology, others have disappointed in late-stage testing. Adding a widely used, orally available drug such as semaglutide to the list of tested candidates made the EVOKE trials among the most closely watched studies in the field.
With publication in a peer-reviewed journal, the scientific community can now examine the methodology, the numbers and the conclusions in detail — and independent researchers will judge whether the evidence supports further work on GLP-1 drugs for the brain.
SciBeat will follow the reaction from Alzheimer's researchers and clinicians as they digest the full dataset.
via Google News: Clinical Trials (Source)
More from Elena Vasquez
Nearby plates
- Semaglutide Tested for Alcohol Use Disorder in New Lancet Trial
- Large Nordic Study Finds No Link Between Semaglutide and Pancreatic Cancer
- Semaglutide Linked to 21% Lower Psychiatric Hospitalization Risk
- Semaglutide and Tirzepatide: Heart Outcomes Compared in Real-World Study
- Muscle-Sparing Antibody Halves Lean Mass Loss from Semaglutide